Bristol-Myers' Opdivo is approved as a skin cancer treatment in Europe

Bristol-Myers Squibb Co. said Friday the drug Opdivo was approved by European regulators as skin cancer treatment.

The drug is already approved the U.S. as a treatment for skin and lung cancer.

The approval allows for the sale of the drug in the 28 countries that belong to the European Union.

Opdivo had $40 million in worldwide revenue during the first quarter of 2015.